Prognostic impact of nm23-H1 and PCNA expression in pathologic stage I non-small cell lung cancer.

INTRODUCTION

The purpose of this study was to evaluate the value of nm23-H1 and proliferating cell nuclear antigen (PCNA) expression as well as other confirmed prognostic factors in predicting the clinical outcome after definitive surgery of pathologic stage I non-small cell lung cancer (NSCLC).

METHODS

Four hundred fifty-two consecutive and non-selected patients who underwent definitive surgery for stage I NSCLC were included in this study. Formalin-fixed paraffin-embedded specimens were stained for nm23-H1 and PCNA, the correlation between the staining and its clinicopathological parameters, and its prognostic power were analyzed statistically.

RESULTS

Of the 452 patients studied, 320 cases (70.8%) were high expression for nm23-H1. A total of 182 carcinomas (40.3%) were PCNA high expression tumors. PCNA expression correlated with serum CEA level (P < 0.001), and differentiation (P < 0.001). In univariate analysis by log-rank test, serum CEA level, pT stage, differentiation, nm23-H1 expression, and PCNA expression were significant prognostic factors (P = 0.037, 0.021, <0.001, 0.042, and 0.014, respectively). In multivariate analysis, pT stage and nm23-H1 expression maintained its independent prognostic influence on overall survival (P = 0.041 and 0.003, respectively).

CONCLUSIONS

nm23-H1 may be a good biomarker to be applied in clinic to predict the prognosis of patients with completely resected pathologic stage I NSCLC.